Aestus Therapeutics and Eisai have entered into a collaboration to research and develop therapeutics for the treatment of psychiatric disorders. The multi-year collaboration will involve preclinical validation of potential therapeutics leading to clinical proof-of-concept studies.

Aestus has identified products with the potential to treat certain psychiatric disorders through its analysis of gene expression data sets, coupled with biological pathway mining on data from relevant disease models. In partnership with Eisai, Aestus will test these products to identify the best candidates for further development.

“Aestus is delighted that this collaboration with Eisai combines our strengths in this ground breaking work to develop novel therapies for people affected by psychiatric disorders. Eisai’s proven talent and expertise will enable us to move drug candidates through the clinical development process efficiently with the goal of bringing innovative new treatments to the market place,” said Tage Honore, chief executive officer and co-founder of Aestus. “It is our hope that the products we discover through this collaboration will improve the quality of life for the millions of sufferers of psychiatric disorders and their families.”